Cited by 1,001Lipoproteins and Cardiovascular HealthCardiac and Coronary Surgery TechniquesCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

Open access

Buchwald, Henry, Varco, Richard L., Matts, John P., Long, John M., Fitch, Laurie L., Campbell, Gilbert S., Pearce, Malcolm B., Yellin, Albert E., Edmiston, W. Allan, Smink, Robert D., Sawin, Henry S., Campos, Christian T., Hansen, Betty J., Tuna, Naip, Karnegis, James N., Sanmarco, Miguel E., Amplatz, Kurt, Castaneda-Zuniga, Wilfredo R., Hunter, David W., Bissett, Joseph K., Weber, Frederic J., Stevenson, James W., Leon, Arthur S., Chalmers, Thomas C.·1990·New England Journal of Medicine

DOI 10.1056/nejm199010043231404

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND AND METHODS: The Program on the Surgical Control of the Hyperlipidemias (POSCH), a randomized clinical trial, was designed to test whether cholesterol lowering induced by the partial ileal bypass operation would favorably affect overall mortality or mortality due to coronary heart disease. The study population consisted of 838 patients (417 in the control group and 421 in the surgery group), both men (90.7 percent) and women, with an average age of 51 years, who had survived a first myocardial infarction. The mean follow-up period was 9.7 years. RESULTS: When compared with the control group at five years, the surgery group had a total plasma cholesterol level 23.3 percent lower (4.71 +/- 0.91 vs. 6.14 +/- 0.89 mmol per liter [mean +/- SD]; P less than 0.0001), a low-density lipoprotein cholesterol level 37.7 percent lower (2.68 +/- 0.78 vs. 4.30 +/- 0.89 mmol per liter; P less than 0.0001), and a high-density lipoprotein cholesterol level 4.3 percent higher (1.08 +/- 0.26 vs. 1.04 +/- 0.25 mmol per liter; P = 0.02). Overall mortality and mortality due to coronary heart disease were reduced, but not significantly so (deaths overall [control vs. surgery], 62 vs. 49, P = 0.164; deaths due to coronary disease, 44 vs. 32, P = 0.113). The overall mortality in the surgery subgroup with an ejection fraction greater than or equal to 50 percent was 36 percent lower (control vs. surgery, 39 vs. 24; P = 0.021). The value for two end points combined--death due to coronary heart disease and confirmed nonfatal myocardial infarction--was 35 percent lower in the surgery group (125 vs. 82 events; P less than 0.001). During follow-up, 137 control-group and 52 surgery-group patients underwent coronary-artery bypass grafting (P less than 0.0001). A comparison of base-line coronary arteriograms with those obtained at 3, 5, 7, and 10 years consistently showed less disease progression in the surgery group (P less than 0.001). The most common side effect of partial ileal bypass was diarrhea; others included occasional kidney stones, gallstones, and intestinal obstruction. CONCLUSIONS: Partial ileal bypass produces sustained improvement in the blood lipid patterns of patients who have had a myocardial infarction and reduces their subsequent morbidity due to coronary heart disease. The role of this procedure in the management of hypercholesterolemia remains to be determined. These results provide strong evidence supporting the beneficial effects of lipid modification in the reduction of atherosclerosis progression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199010043231404

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Practical Nonparametric Statistics
Groggel, D. J., & Conover, W. J. (2000) · Technometrics · doi:10.2307/1271101 · Cited by 11,076
Immunochemical quantitation of antigens by single radial immunodiffusion
Mancini, G., Carbonara, A. O., & Heremans, J. F. (1965) · Immunochemistry · doi:10.1016/0019-2791(65)90004-2 · Cited by 9,091
Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
A Generalized Wilcoxon Test for Comparing Arbitrarily Singly-Censored Samples
Gehan, E. A. (1965) · Biometrika · doi:10.1093/biomet/52.1-2.203 · Cited by 3,407
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels
Castelli, W. P. (1986) · JAMA · doi:10.1001/jama.256.20.2835 · Cited by 2,512
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.
Kannel, W., Castelli, W., Gordon, T., & McNamara, P. M. (2020) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-1 · Cited by 2,160

Show all 58 references

Research works printed but not linked: 29

10.1001/jama.256.20.2823 · DOI · Paper page
Leren, 1966, Acta Med Scand Suppl, 466, 1
1968, Lancet, 2, 693
Frantz, 1975, Circulation, 52, II-4
10.1001/jama.231.4.360 · DOI
10.1001/jama.251.3.351 · DOI · Paper page
10.1001/jama.257.23.3233 · DOI
Buchwald H. Intestinal bypass for hypercholesterolemia. In: Nyhus LM, Baker RJ, eds. Mastery of surgery. Vol. 3. Boston: Little, Brown, 1984:901–7.
Buchwald H, Campos CT. Partial ileal bypass for control of hyperlipidemia and atherosclerosis. In: Sabiston DC Jr, Spencer FC, eds. Surgery of the chest. 5th ed. Philadelphia: W.B. Saunders, 1990:1799–819.
Schouten, 1986, Artery, 13, 240
1959, Stat Bull Metrop Life Insur Co, 40, 1
Bruce, 1971, Ann Clin Res, 3, 323
National Heart and Lung Institute, Lipid Research Clinics Program. Manual of laboratory operations. Vol. 1. Bethesda, Md.: National Institutes of Health, 1974. (DHEW publication no. (NIH) 75–628.)
1970, Bull World Health Organ, 43, 891
Mantel, 1966, Cancer Chemother Rep, 50, 163
Matts, Controlled Clin Trials
Campos, 1987, Surgery, 102, 424
Campos, 1988, Curr Surg, 45, 380
Campos, 1988, Surg Forum, 39, 193
Addison, 1851, Guys Hosp Rep, 2, 267
Ignatovski, 1908, Izviest Imp Voyenno-med Akad S Petersb, 16, 154
Anitschkow, 1913, Centralbl Allg Pathol Pathol Anat, 24, 1
Wacker, 1913, Münchener Med Wochenschr, 60, 2097
European Coronary Surgery Study Group, 1982, Lancet, 2, 1173
Buchwald, 1965, Surgery, 58, 22
Scott, 1967, Surg Gynecol Obstet, 125, 3
Buchwald, 1963, Circulation, 28, II-649
Moore, 1969, Surgery, 65, 98
Buchwald, Ann Surg

Sorted by citations

Items 301–400 of 1,000

Pathological Changes in Acute Coronary Syndromes: The Role of Statin Therapy in the Modulation of Inflammation, Endothelial Function and Coagulation
Ray, K., & Cannon, C. (2004) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-004-0205-9 · Cited by 43
Regression of Coronary Atherosclerosis
Loscalzo, J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231909 · Cited by 42
The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials
Daida, H., Dohi, T., Fukushima, Y., Ohmura, H., & Miyauchi, K. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48603 · Cited by 41
Colesterol LDL y aterosclerosis: evidencias
Guijarro, C., & Cosı́n-Sales, J. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.12.004 · Cited by 41
Long-Term Effects of Dietary Fiber Supplementation on Serum Glucose and Lipoprotein Levels In Diabetic Rats Fed a High Cholesterol Diet.
Hozumi, T., Yoshida, M., Ishida, Y., MIMOTO, H., SAWA, J., Doi, K., & Kazumi, T. (1995) · Endocrine Journal · doi:10.1507/endocrj.42.187 · Cited by 41
Effecacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for prevention of stroke
Warshafsky, S., Packard, D., Marks, S., Sachdeva, N., Terashita, D., Kaufman, G., Sang, K., Deluca, A., Peterson, S. J., & Frishman, W. (1999) · Journal of general internal medicine · doi:10.1046/j.1525-1497.1999.02109.x · Cited by 24
Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction
Hirsch, A. T., & Gotto, A. M. (2002) · Vascular Medicine · doi:10.1191/1358863x02vm453ra · Cited by 40
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study
van Lennep, H. W. O. R., Liem, A. H., Dunselman, P. H. J. M., Dallinga‐Thie, G. M., Zwinderman, A. H., & Jukema, J. W. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x273273 · Cited by 40
Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT).
Kleemann, A., Eckert, S., von Eckardstein, A., Lepper, W., Schernikau, U., Gleichmann, U., Hanrath, P., Fleck, E., Neiss, A., Kerber, S., et al. (1999) · European Heart Journal · doi:10.1053/euhj.1999.1483 · Cited by 38
Atherosclerosis: inhibition of regression as therapeutic possibilities.
Davies, M. J., KRIKLER, D. M., & Katz, D. R. (1991) · Heart · doi:10.1136/hrt.65.6.302 · Cited by 40
Natural history of coronary atherosclerosis using quantitative angiography in men, and implications for clinical trials of coronary regression
Stone, P. H., Gibson, C. M., Pasternak, R. C., McManus, K., Diaz, L., Boucher, T. M., Spears, R., Sándor, T., ROSNER, B. A., & Sacks, F. M. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90821-s · Cited by 40
Beyond Low-Density Lipoprotein Cholesterol
Rosenson, R. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440110036006 · Cited by 42
The influence of pretreatment lew density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials
Sacks, F. M., Gibson, C. M., ROSNER, B. A., Pasternak, R. C., & Stone, P. H. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80475-5 · Cited by 40
The emerging concept of “individualized cholesterol-lowering therapy”: A change in paradigm
Lütjohann, D., Stellaard, F., Mulder, M. T., Sijbrands, E. J. G., & Weingärtner, O. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.004 · Cited by 41
Targeted metabolomics study of serum bile acid profile in patients with end-stage renal disease undergoing hemodialysis
Li, R., Zeng, L., Xie, S., Chen, J., Yu, Y., & Zhong, L. (2019) · PeerJ · doi:10.7717/peerj.7145 · Cited by 40
Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study☆
Baldassarre, D., Veglia, F., Gobbi, C., Gallus, G., Ventura, A., Crepaldi, G., Fisicaro, M., Rimondi, S., Ricci, G., & Mancini, M. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00434-7 · Cited by 39
Variability gene effects of DNA polymorphisms at the apo B, apo AI/C III and apo E loci on serum lipids: the Cardiovascular Risk in Young Finns Study
Porkka, K., TAIMELA, S. P., KONTULA, K. K., Lehtimäki, T. J., Aalto‐Setälä, K., Åkerblom, H. K., & Viikari, J. S. A. (1994) · Clinical Genetics · doi:10.1111/j.1399-0004.1994.tb04007.x · Cited by 39
Inhibition of ileal sodium-dependent bile acid transport by 2164U90.
Root, C., Smith, C. D., Winegar, D. A., Brieaddy, L. E., & Lewis, M. C. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39869-2 · Cited by 39
The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention
Texter, M. J., Lees, R. S., Pitt, B., Dinsmore, R. E., & Uprichard, A. C. G. (1993) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00878518 · Cited by 39
Aggressive lipid therapy in the statin era
FARMER, J. (1998) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(98)80006-6 · Cited by 38
HYPERLIPIDEMIA
Yu, J. N., Cunningham, J. A., Thouin, S. R., Gurvich, T., & Liu, D. (2000) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(05)70164-0 · Cited by 41
Apparent selective bile acid malabsorption as a consequence of ileal exclusion: effects on bile acid, cholesterol, and lipoprotein metabolism.
Åkerlund, J., Björkhem, I., Angelin, B., Liljeqvist, L., & Einarsson, K. (1994) · Gut · doi:10.1136/gut.35.8.1116 · Cited by 38
Diet, Lifestyle, and Nonstatin Trials: Review of Time to Benefit
Denke, M. A. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.014 · Cited by 38
Serial quantitative coronary angiography and coronary events
Mack, W. J., Xiang, M., Selzer, R. H., & Hodis, H. N. (2000) · American Heart Journal · doi:10.1067/mhj.2000.105702 · Cited by 37
Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease.
Brown, B. G., Zhao, X., Sacco, D., & Albers, J. J. (1993) · Annual Review of Medicine · doi:10.1146/annurev.me.44.020193.002053 · Cited by 38
Gene therapy for the vulnerable plaque
Feldman, L. J., & Isner, J. M. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00235-v · Cited by 37
Aorta and coronary angiographic follow‐up of children with severe hypercholesterolemia treated with low‐density lipoprotein apheresis
Stefanutti, C., Vivenzio, A., Giacomo, S. D., Mazzarella, B., Bosco, G., & Berni, A. (2009) · Transfusion · doi:10.1111/j.1537-2995.2009.02135.x · Cited by 36
Therapies for diabetic dyslipidaemia
Bell, D. S. H., Badarin, F. J. A., & O’Keefe, J. H. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01342.x · Cited by 36
Progression of coronary artery disease is dependent on anatomic location and diameter
Jost, S., Deckers, J. W., Nikutta, P., Rafflenbeul, W., Wiese, B., Hecker, H., Lippolt, P., & Lichtlen, P. R. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90306-l · Cited by 36
Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B.
Zhao, X.-Q., Brown, B. G., Hillger, L. A., Sacco, D., Bisson, B., Fisher, L. D., & Albers, J. J. (1993) · Circulation · doi:10.1161/01.cir.88.6.2744 · Cited by 35
Principal results of the Hypertension and Lipid Trial (HALT): A multicenter study of doxazosin in patients with hypertension
Levy, D. A., Walmsley, P., & Levenstein, M. (1996) · American Heart Journal · doi:10.1016/s0002-8703(96)90181-7 · Cited by 36
Measuring progression and regression of coronary atherosclerosis in clinical trials: problems and progress
Lesp�rance, J., & Waters, D. D. (1992) · International journal of cardiac imaging · doi:10.1007/bf01146835 · Cited by 36
Plaque stabilization: A mechanism for the beneficial effect of lipid-lowering therapies in angiography studies
Waters, D. D. (1994) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(05)80038-6 · Cited by 35
A novel class of apical sodium co-dependent bile acid transporter inhibitors: The 1,2-Benzothiazepines
Tollefson, M. B., Kolodziej, S. A., Fletcher, T., Vernier, W. F., Beaudry, J. A., Keller, B. T., & Reitz, D. B. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.08.004 · Cited by 35
What the Statin Trials Have Taught Us
Waters, D. D. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.066 · Cited by 35
The Future of Bariatric Surgery
Buchwald, H. (2005) · Obesity Surgery · doi:10.1381/0960892053923761 · Cited by 35
Self-citation
Novel non-systemic inhibitor of ileal apical Na+-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys
Kitayama, K., Nakai, D., Kono, K., van der Hoop, A. G., Kurata, H., de Wit, E. C., Cohen, L. H., Inaba, T., & Kohama, T. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.04.005 · Cited by 34
Despite good compliance, very low fat diet alone does not achieve recommended cholesterol goals in outpatients with coronary heart disease
Aquilani, R. (1999) · European Heart Journal · doi:10.1053/euhj.1999.1402 · Cited by 35
Regression of atherosclerosis: A review
SCHELL, W., & MYERS, J. N. (1997) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(97)80041-2 · Cited by 35
Evaluation of Colestipol/Niacin Therapy With Computer‐Derived Coronary End Point Measures: A Comparison of Different Measures of Treatment Effect
Blankenhorn, D., Selzer, R., Mack, W., Crawford, D., Pogoda, J., Lee, P., Shircore, A., & Azen, S. (1992) · Circulation · doi:10.1161/01.cir.86.6.1701 · Cited by 45
How bariatric and metabolic operations control metabolic syndrome
Ikramuddin, S., & Buchwald, H. (2011) · British journal of surgery · doi:10.1002/bjs.7652 · Cited by 34
Self-citation
Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22013 · Cited by 37
Zinc salts precipitate unconjugated bilirubin in vitro and inhibit enterohepatic cycling of bilirubin in hamsters
Méndez‐Sánchez, N., Roldán-Valadéz, E., Flores, M. A., Cárdenas-Vázquez, R., & Uribe, M. (2001) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2001.00879.x · Cited by 34
The prevention of cardiovascular disease: Emphasis on Secondary Prevention
Robinson, J. G., & Leon, A. S. (1994) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30177-8 · Cited by 34
Self-citation
Hypobetalipoproteinemia Is Associated With Low Levels of Hemostatic Risk Factors in the Framingham Offspring Population
Welty, F. K., Mittleman, M. A., Wilson, P. W. F., Sutherland, P. A., Matheney, T. H., Lipinska, I., Muller, J. E., Levy, D. A., & Tofler, G. H. (1997) · Circulation · doi:10.1161/01.cir.95.4.825 · Cited by 33
Regression of atherosclerosis in humans by lowering serum cholesterol
Yamamoto, A. (1991) · Atherosclerosis · doi:10.1016/0021-9150(91)90002-k · Cited by 34
Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation
Barbir, M., Rose, M., Kushwaha, S. S., Akl, S. G., Mitchell, A. G., & Yacoub, M. H. (1991) · International Journal of Cardiology · doi:10.1016/0167-5273(91)90353-q · Cited by 34
Overall Mortality in the Program on the Surgical Control of the Hyperlipidemias1
Buchwald, H., Williams, S. E., Matts, J. P., Nguyen, P. A., & Boen, J. R. (2002) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(02)01275-9 · Cited by 33
Self-citation
Dyslipidemia and Risk of Coronary Heart Disease: Role of Lifestyle Approaches for Its Management
Leon, A. S., & Bronas, U. G. (2009) · American Journal of Lifestyle Medicine · doi:10.1177/1559827609334518 · Cited by 34
Self-citation
Inflammation, Insulin Resistance, Infection, Diabetes, and Atherosclerosis
Bell, D. S. H. (2000) · Endocrine Practice · doi:10.4158/ep.6.3.272 · Cited by 33
Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias
FODOR, J. G., Frohlich, J. J., & McPherson, P. R. (2000) · Cited by 33
Angiographic and Clinical Progression in Unstable Angina
Théroux, P. (1995) · Circulation · doi:10.1161/01.cir.91.9.2295 · Cited by 33
Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group.
Tamura, A., Mikuriya, Y., & Nasu, M. (1997) · American Journal of Cardiology · doi:10.1016/s0002-9149(97)00010-6 · Cited by 38
Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
Insull, W., Black, D. M., Dujovne, C. A., Hosking, J. D., Hunninghake, D. B., Keilson, L., Knopp, R. H., McKenney, J. M., Stein, E. A., & Troendle, A. J. (1994) · PubMed · Cited by 33
New cholesterol guidelines: Worth the wait?
Raymond, C. E., Cho, L., Rocco, M. B., & Hazen, S. L. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13161 · Cited by 33
Progressive intrahepatic cholestasis: Mechanisms, diagnosis and therapy
Shneider, B. L. (2004) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2004.00240.x · Cited by 32
Inhibition of ileal apical but not basolateral bile acid transport reduces atherosclerosis in apoE−/− mice
Lan, T., Haywood, J., & Dawson, P. A. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.05.017 · Cited by 32
Cholesterol lowering, low cholesterol, and mortality
LaRosa, J. C. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)91062-m · Cited by 32
Calcium channel blockers and coronary atherosclerosis: from the rabbit to the real world.
Waters, D. D., & Lespérance, J. (1994) · American Heart Journal · doi:10.1016/0002-8703(94)90253-4 · Cited by 33
Disorders of Lipid Metabolism
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00037-7 · Cited by 32
Heart disease in patients with diabetes mellitus
Sniderman, A. D., Michel, C., & Racine, N. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90197-u · Cited by 31
Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene.
Karayan, L., Qiu, S., Bétard, C., Dufour, R., Roederer, G. O., Minnich, A., Davignon, J., & Genest, J. (1994) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.14.8.1258 · Cited by 31
The Lipoprotein and Coronary Atherosclerosis Study (LCAS): Design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia
West, M. S., Herd, J. A., Ballantyne, C. M., Pownall, H. J., Simpson, S., Gould, K. L., & Gotto, A. M. (1996) · Controlled Clinical Trials · doi:10.1016/s0197-2456(96)00178-x · Cited by 30
S-8921, an ileal Na+/bile acid cotransporter inhibitor decreases serum cholesterol in hamsters
Hara, S., Higaki, J., Higashino, K., Iwai, M., Takasu, N., Miyata, K., Tonda, K., Nagata, K., Goh, Y., & Mizui, T. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00242-7 · Cited by 31
Diagnostic et traitement des hypercholestérolémies familiales (HF) chez l’adulte : recommandations de la Nouvelle société française d’athérosclérose (NSFA)
Farnier, M., Bruckert, É., Boileau, C., & Krempf, M. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.01.053 · Cited by 30
Ezetimibe Improves Endothelial Function and Inhibits Rho-Kinase Activity Associated With Inhibition of Cholesterol Absorption in Humans
Nochioka, K., Tanaka, S.-I., Miura, M., Do.e, Z., Fukumoto, Y., Shiba, N., & Shimokawa, H. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0331 · Cited by 30
Effects of Atorvastatin on the Different Phases of Atherogenesis
Rubba, P. (2007) · Drugs · doi:10.2165/00003495-200767001-00003 · Cited by 30
Getting cardiologists interested in lipids
Roberts, W. C. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90898-m · Cited by 30
Efficacy and Tolerability of Fluvastatin and Bezafibrate in Patients with Hyperlipidemia and Persistently High Triglyceride Levels
Spieker, L. E., Noll, G., Hannak, M., & Lüscher, T. F. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200003000-00003 · Cited by 30
Low serum cholesterol, cancer and other noncardiovascular disorders
Epstein, F. H. (1992) · Atherosclerosis · doi:10.1016/0021-9150(92)90182-g · Cited by 30
The Farnesoid X Receptor A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism
Rader, D. J., Hama, S. Y., Hough, G. P., Yu, N., & Ansell, B. J. (2005) · Cited by 29
Plasma lipids and cardiovascular risk: a POSCH report
Buchwald, H. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00467-6 · Cited by 29
Self-citation
Plasma Cholesterol: An Influencing Factor in Red Blood Cell Oxygen Release and Cellular Oxygen Availability
Buchwald, H., Menchaca, H. J., Michalek, V. N., Rohde, T. D., Hunninghake, D. B., & O’Dea, T. J. (2000) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(00)00704-3 · Cited by 29
Self-citation
Current strategies in the diagnosis and management of lower extremity peripheral vascular disease
Wilt, T. J. (1992) · Journal of General Internal Medicine · doi:10.1007/bf02599110 · Cited by 29
Metabolic surgery: a brief history and perspective
Buchwald, H. (2009) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2009.09.001 · Cited by 29
Self-citation
Effect of Different Antilipidemic Agents and Diets on Mortality. A Systematic Review
Studer, M., Briel, M., Leimenstoll, B. M., Glass, T. R., & Bucher, H. C. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.06.022 · Cited by 27
Low‐Density Lipoprotein Apheresis: Clinical Results with Different Methods
Bambauer, R. (2002) · Artificial Organs · doi:10.1046/j.1525-1594.2002.06837.x · Cited by 28
Low‐Density Lipoprotein Apheresis for Prevention and Regression of Atherosclerosis: Clinical Results
Bambauer, R., Olbricht, C. J., & Schoeppe, E. (1997) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.1997.tb00145.x · Cited by 27
Secondary Prevention for Ischemic Heart Disease
Miller, D. B. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440390031005 · Cited by 28
Biological and Medical Aspects of Active Heal Transport of Bile Acids
Hofmann, A. F., Schteingart, C. D., & Lillienau, J. (1991) · Annals of Medicine · doi:10.3109/07853899109148043 · Cited by 28
The effects of lowering serum cholesterol on coronary heart disease risk
Rossouw, J. E. (1994) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30182-1 · Cited by 28
Retardation of Coronary Atherosclerosis: The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and Other Angiographic Trials
de Faire, U., Ericsson, C., Grip, L., Nilsson, J., Svane, B., & Hamsten, A. (1997) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007787713191 · Cited by 21
Statins prevent coronary heart disease.
Oliver, M. F. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92399-3 · Cited by 29
Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease
Trauner, M., Karpen, S. J., & Dawson, P. A. (2025) · Hepatology · doi:10.1097/hep.0000000000001438 · Cited by 27
Clinical experience with ezetimibe/simvastatin in a Mediterranean population
Migdalis, I. N., Efthimiadis, A., Pappas, S., Alexopoulos, D., Vlasserou, F., & Mikhailidis, D. P. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903169031 · Cited by 27
Predictive Value of Lipid Profile for Salutary Coronary Angiographic Changes in Patients on a Low-Fat Diet and Physical Exercise Program
Niebauer, J., Hambrecht, R., Velich, T., Marburger, C., Hauer, K. A., Kreuzer, J., Zimmermann, R., von Hodenberg, E., Schlierf, G., Schuler, G. C., et al. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)90390-2 · Cited by 27
The clinical and economic significance of atherosclerosis
Stone, N. J. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00315-4 · Cited by 27
Screening for cardiovascular disease with cholesterol
SULLIVAN, D. R. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00720-3 · Cited by 27
Symposium on regression of atherosclerosis
Moncada, S., Martin, J., & Higgs, A. (1993) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1993.tb00781.x · Cited by 27
Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension
Carruthers, G., Dessain, P., Fodor, G. J., Newman, C., Palmer, W. H., & Sim, D. A. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90514-d · Cited by 27
Metabolic, Renal, and Nutritional Consequences of Bariatric Surgery: Implications for the Clinician
Chauhan, V., Vaid, M., Gupta, M., Kalanuria, A. A., & Parashar, A. (2010) · Southern Medical Journal · doi:10.1097/smj.0b013e3181e6cc3f · Cited by 27
Kidney Function, Cholesterol Absorption and Remnant Lipoprotein Accumulation in Patients with Diabetes Mellitus
Sonoda, M., Shoji, T., Kimoto, E., Okute, Y., Shima, H., Naganuma, T., Motoyama, K., Morioka, T., Mori, K., Fukumoto, S., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.20594 · Cited by 26
Atherosclerosis--reversal with therapy.
Blankenhorn, D. H., & Hodis, H. N. (1993) · PubMed Central · Cited by 26
Pitavastatin: evidence for its place in treatment of hypercholesterolemia
Alagona, P. (2010) · Core evidence · doi:10.2147/ce.s8008 · Cited by 26
Role of non–high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials
Xydakis, A. M., & Ballantyne, C. M. (2003) · Current Opinion in Cardiology · doi:10.1097/00001573-200311000-00012 · Cited by 25
Evolution of coronary atherosclerosis in patients with mild coronary artery disease studied by serial quantitative coronary angiography at 2 and 4 years follow-up
Vos, J., de Feyter, P. J., Kingma, J. H., Emanuelsson, H., Legrand, V., Winkelmann, B. R., Dumont, J. M., & Simoons, L. M. (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015401 · Cited by 26
Definition and measurement of restenosis after successful coronary angioplasty: Implications for clinical trials
Lespérance, J., Bourassa, M. G., Schwartz, L., Hudon, G., Laurier, J., Eastwood, C., & Kazim, F. (1993) · American Heart Journal · doi:10.1016/0002-8703(93)91013-5 · Cited by 26
Effect of cholesterol reduction by simvastatin on progression of coronary atherosclerosis: Design, baseline characteristics, and progress of the Multicenter Anti-Atheroma Study (MAAS)
Dumont, J. (1993) · Controlled Clinical Trials · doi:10.1016/0197-2456(93)90004-w · Cited by 26
Cholesterol and Violent Behavior
Santiago, J. M. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.12.1317 · Cited by 26
Clinical lipidology at the end of the millennium
Thompson, G. R., & Barter, P. J. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199912000-00007 · Cited by 26

Authors: Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., Sawin, H. S., Campos, C. T., Hansen, B. J., Tuna, N., Karnegis, J. N., Sanmarco, M. E., Amplatz, K., Castaneda-Zuniga, W. R., Hunter, D. W., Bissett, J. K., Weber, F. J., Stevenson, J. W., Leon, A. S., & Chalmers, T. C.
Affiliations: University of Minnesota (US)
University of Southern California (US)
ORCID: Long, John M.
Hunter, David W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1990-10-04
Volume: 323
Issue: 14
Pages: 946-955
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199010043231404
OpenAlex: W2331959986
Cited by: 1,001
References: 58
Citations by year: 2026: 3 · 2025: 2 · 2024: 3 · 2023: 9 · 2022: 5 · 2021: 20 · 2020: 11 · 2019: 16 · 2018: 10 · 2017: 11 · 2016: 22 · 2015: 15 · 2014: 17 · 2013: 12 · 2012: 17
FWCI: 84.71
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Surgery › Cardiac and Coronary Surgery Techniques
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: partial ileal bypass, hypercholesterolemia, coronary artery disease, mortality, myocardial infarction, cholesterol lowering, LDL cholesterol, HDL cholesterol, first myocardial infarction, coronary artery bypass grafting, ejection fraction, long-term outcomes, nonfatal myocardial infarction
MeSH terms: Adult, Coronary Disease, Electrocardiography, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Hyperlipidemias, Jejunoileal Bypass, Lipids, Male, Middle Aged, Ultrasonography, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Coronary Angiography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks